Research
Berberine
253 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial.
This randomized clinical trial evaluated the efficacy and safety of berberine in reducing visceral adipose tissue (VAT) area and liver fat content in diabetes-free individuals with obesity and MASLD. The study found no significant differences between berberine and placebo groups for VAT area or liver fat content. However, berberine was associated with larger reductions in low-density lipoprotein cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein levels.
The effects of Gegen Qinlian decoction and its main constituents on glucolipid metabolic disorders in diabetes: an overview of systematic reviews and meta-analysis.
This overview of systematic reviews and meta-analysis evaluates the efficacy and safety of Gegen Qinlian decoction (GQD) and its main constituents, berberine and puerarin, in managing glucolipid metabolic disorders in diabetes mellitus. The evidence suggests that GQD, berberine, and puerarin are effective in improving anti-diabetes roles and blood lipid profiles, reducing total cholesterol, triglycerides, and LDL-c while increasing HDL-c.
Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials.
Systematic review and meta-analysis evaluating the efficacy and safety of berberine on metabolic syndrome components. Berberine significantly reduces triglycerides, fasting plasma glucose, and waist circumference, and improves LDL-C, total cholesterol, BMI, and 2-h oral glucose tolerance. No significant safety differences were observed between berberine and placebo.
Time-dose response and mechanistic specificity of berberine in renal fibrosis from a multi-model integration perspective: a systematic review and meta-analysis on animal models.
Systematic review and meta-analysis of 26 animal studies evaluating berberine's efficacy and mechanisms in renal fibrosis. Berberine significantly lowered serum creatinine, blood urea nitrogen, and oxidative stress markers, with efficacy in the 100-400 mg/kg dose range over 5-12 weeks. Mechanisms were model-dependent, involving AMPK/PPARα pathway and ferroptosis in UUO model, and glycolipid metabolism and epigenetic regulation in DN model.
Berberine and health outcomes: an overview of systematic reviews.
Systematic review of 54 SRs evaluating berberine's effects on various chronic diseases. Berberine showed significant improvements in outcomes for type 2 diabetes, gastrointestinal disorders, schizophrenia, metabolic syndrome, and dyslipidemia. However, the quality of the included SRs was generally low.
The therapeutic effect of Berberine on rodent models of kidney injury: a systematic review and meta - analysis.
This systematic review and meta-analysis evaluated the effects of berberine on acute kidney injury (AKI) in rodent models. The analysis of 19 studies showed significant improvements in renal function metrics, such as blood urea nitrogen and serum creatinine, and reductions in inflammatory markers, indicating berberine's renal protective effects.
Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research.
Systematic review and meta-analysis of berberine's effects on non-alcoholic fatty liver disease (NAFLD) across clinical and preclinical studies. Berberine significantly reduced fasting blood glucose levels in clinical studies and showed benefits in biochemical markers like ALT, AST, and lipid profiles in preclinical settings.
The effect of berberine on obesity indices: a systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the effect of berberine on obesity indices. Berberine significantly reduced body weight, BMI, and WC, but did not significantly reduce WHR. The analysis included 23 articles and highlighted the need for improved reporting standards in future trials.
Neuroprotective effects of berberine in preclinical models of ischemic stroke: a systematic review.
Systematic review of 18 preclinical studies evaluating berberine's neuroprotective effects in animal models of ischemic stroke. Berberine significantly reduced infarct volume, improved neurological function, and exhibited anti-inflammatory, antioxidant, anti-apoptotic, and neuroregenerative effects.
Preventive effects of chemical drugs on recurrence of colorectal adenomas: systematic review and Bayesian network meta-analysis.
Systematic review and Bayesian network meta-analysis of 45 RCTs evaluating the preventive effects of chemical drugs on the recurrence of colorectal adenomas. DFMO + Sulindac significantly reduced recurrence but with high adverse event risk. Berberine showed promise for clinical development due to better safety, tolerance, and compliance.
Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: A systematic review and meta-analysis.
Systematic review and meta-analysis of 10 RCTs with 952 patients assessing berberine plus 5-ASA for ulcerative colitis. Berberine improved clinical efficacy, reduced disease activity and inflammatory markers, and modulated immune responses, but did not significantly reduce adverse reactions.
The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.
This meta-analysis assessed the efficacy and safety of berberine in treating non-alcoholic fatty liver disease (NAFLD) across 10 RCTs involving 811 patients. Berberine significantly improved liver enzymes, lipid profile, and insulin sensitivity, with a favorable safety profile and only mild gastrointestinal adverse events reported.
Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.
Meta-analysis of 10 RCTs involving 713 patients evaluating berberine as adjuvant therapy for reduced fertility potential in women with PCOS. Berberine improved endometrial thickness, ovulation rate, and clinical pregnancy rate, and reduced luteinizing hormone and total testosterone levels compared to Western medicine alone.
Neuroprotective effects and possible mechanisms of berberine in animal models of Alzheimer's disease: a systematic review and meta-analysis.
Systematic review and meta-analysis of 22 animal studies assessing the neuroprotective effects of berberine on Alzheimer's disease models. Berberine significantly improved cognitive outcomes and reduced amyloid beta deposition, tau phosphorylation, and markers of oxidative stress and inflammation. Potential mechanisms include anti-neuroinflammation, anti-oxidative stress, modulation of autophagy, and protection of the cholinergic system.
Effect of berberine on cognitive function and β-amyloid precursor protein in Alzheimer's disease models: a systematic review and meta-analysis.
Systematic review and meta-analysis of 19 studies involving 360 animals, evaluating the effects of berberine on cognitive function and β-amyloid precursor protein in Alzheimer's disease models. Berberine decreased escape latency, increased platform crossings and time in the target quadrant, and regulated APP expression, suggesting improved cognitive function and potential neuroprotective effects.
Berberine in rheumatoid arthritis: a comprehensive review and meta-analysis of its anti-inflammatory and immunomodulatory mechanisms in animal models.
This meta-analysis reviewed the anti-inflammatory and immunomodulatory mechanisms of berberine in animal models of rheumatoid arthritis. The findings showed that berberine lowers levels of inflammatory cytokines and improves histopathological scores, indicating its potential anti-inflammatory, anti-oxidative stress, and osteoprotective qualities.
Berberine as a new neuraminidase inhibitor drug: A systematic review
Systematic review focusing on the anti-influenza effects of berberine, highlighting its role in inhibiting neuraminidase (NA) of the influenza virus. Berberine and its derivatives demonstrate antiviral effects, including inhibition of the influenza virus through NA blockade.
Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
Systematic review of 73 studies (nine clinical and 64 pre-clinical) on the effects of Berberine in non-alcoholic fatty liver disease (NAFLD). Berberine impacts NAFLD pathophysiology mechanisms and shows a measurable reduction of liver fat and improved serum lipid and hepatic enzyme profiles in human studies.
Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review.
This systematic review explored the anti-seizure and anti-epileptic effects of berberine (BBR) and its mechanisms. BBR demonstrated neuroprotective properties by reducing oxidative stress, neuroinflammation, and apoptosis, and by increasing brain-derived neurotrophic factor release. It also showed antioxidant and anti-inflammatory activities, modulating neuronal excitability in the brain.
Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of 41 RCTs with 4,838 patients assessing berberine's impact on lipid concentrations in hyperlipidemia. Berberine significantly reduced total cholesterol, LDL, and triglycerides while raising HDL. Combination with other nutraceuticals like red yeast rice and Silybum marianum showed enhanced effects.
Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 44 RCTs with 4606 patients evaluating berberine for cardiovascular diseases. Berberine alone showed no significant improvement in cholesterol levels but reduced NIHSS score, hs-CRP, IL-6, TNF-α, and IMT levels. Berberine plus statins improved TC, TG, LDL-C, NIHSS score, hs-CRP, TNF-α, IMT, Crouse score, and unstable plaques. No significant adverse reactions were reported.
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Systematic review and meta-analysis of 18 RCTs with 1788 participants assessing berberine's effects on dyslipidemia. Berberine reduced LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and increased HDL cholesterol with sex-specific effects. No serious adverse events were reported, though gastrointestinal issues were more frequent with berberine.
Effects of adjuvant berberine therapy on acute ischemic stroke: A meta‐analysis
Meta-analysis of 17 clinical trials involving 1670 patients with acute ischemic stroke (AIS) evaluating berberine (BBR) as an adjuvant therapy. BBR significantly reduced inflammatory markers, improved heart health indicators, and enhanced immune system indicators compared to conventional treatment alone.
Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials.
Systematic review and dose-response meta-analysis of 18 RCTs with 1600 participants assessing berberine/barberry effects on inflammatory biomarkers. Berberine/barberry significantly reduced IL-6, TNF-α, and CRP levels, with a dose-dependent effect observed for doses <1000 mg/day over less than 5 weeks.
Efficacy and safety of berberine for premature ventricular contractions: a meta-analysis and systematic review of randomized controlled trials.
Meta-analysis and systematic review of 10 RCTs with 896 participants assessing the efficacy and safety of berberine for premature ventricular contractions (PVCs). Berberine combined with antiarrhythmic drugs showed a higher effective rate with no significant adverse reactions, while berberine alone had a lower incidence of adverse reactions and recurrence rate.
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
RCT comparing the efficacy and safety of berberine triple therapy to vonoprazan and rabeprazole quadruple therapies for initial H. pylori treatment in 300 patients. Berberine therapy showed comparable eradication rates and was well tolerated, suggesting it as a viable option for H. pylori treatment.
Berberine derivatives as inhibitors of acetylcholinesterase: A systematic review.
Systematic review of berberine derivatives as inhibitors of acetylcholinesterase for Alzheimer's disease management. The review highlights structure-activity relationship and biological activity of new derivatives for potential cholinesterase inhibitory properties.
Berberine and health outcomes: An umbrella review.
This umbrella review summarizes evidence from meta-analyses on berberine's effects on health outcomes. Berberine significantly affects blood glucose levels, insulin resistance, blood lipids, body parameters, inflammatory markers, colorectal adenomas, and Helicobacter pylori infections. Common side effects include gastrointestinal symptoms. The review highlights the need for high-quality RCTs to confirm clinical effects.
The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials.
Meta-analysis of 52 RCTs involving 4616 patients with metabolic syndrome and related disorders. Berberine significantly reduced inflammatory markers such as CRP, TNF-α, and IL-6, but not IL-1β.
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis.
Systematic review and meta-analysis of 37 RCTs involving 3,048 patients with type 2 diabetes, assessing the glucose-lowering effects of berberine. Berberine significantly reduced FPG, HbA1c, and 2hPBG levels without increasing the risk of hypoglycemia or adverse events.
Effects berberine-silymarin on liver enzymes: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 5 RCTs with 549 participants assessing the effect of berberine and silymarin on liver enzymes ALT and AST. No significant reduction in liver enzymes was found following BBR-silymarin consumption.
Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
This randomized controlled trial compared the efficacy and safety of a triple therapy containing berberine, amoxicillin, and rabeprazole to a standard bismuth-containing quadruple therapy for H. pylori eradication in treatment-naive patients. The study found that the berberine triple therapy was noninferior to the quadruple therapy in terms of eradication rates, with fewer adverse events reported in the berberine group.
Pharmacological effects of berberine on models of ulcerative colitis: A meta-analysis and systematic review of animal studies.
Meta-analysis and systematic review of 29 animal studies involving 508 animals assessing the effects of berberine on ulcerative colitis models. Berberine reduced disease activity index scores, alleviated colon length loss, prevented weight loss, and reduced histological colitis scores. It also modulated inflammatory and anti-inflammatory factors, suggesting potential benefits for gut health and inflammation.
Neuroprotective Effect and Possible Mechanisms of Berberine in Diabetes-Related Cognitive Impairment: A Systematic Review and Meta-Analysis of Animal Studies.
This systematic review and meta-analysis evaluated the effect and possible mechanisms of berberine in animal models of diabetes-related cognitive impairment (DCI). The analysis included 20 studies with 442 animals, showing that berberine significantly improved fasting blood glucose, learning, and memory, and reduced oxidative stress and inflammation. The findings suggest berberine's potential in regulating glucose and lipid metabolism, improving insulin resistance, and enhancing the cholinergic system.
Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.
This double-blinded, placebo-controlled randomized study evaluated the combined effect of berberine and probiotics on postprandial hyperlipidemia in 365 type 2 diabetes patients. The combination was more effective than either treatment alone in reducing postprandial total cholesterol and low-density lipoprotein cholesterol levels, suggesting a synergistic hypolipidemic effect and improved cardiovascular risk control.
Efficacy and Underlying Mechanism of Berberine Against Atherosclerosis: A Meta-Analysis in Preclinical Animal Studies.
Meta-analysis of 16 preclinical studies involving 312 ApoE -/- mice to evaluate the effects of berberine on atherosclerosis. Berberine significantly decreased plaque area and macrophage content, lowered levels of TC, triglyceride, and LDL, and altered inflammatory cytokine secretion, indicating its potential in treating atherosclerosis.
Protective effect of berberine in diabetic nephropathy: A systematic review and meta-analysis revealing the mechanism of action.
Systematic review and meta-analysis evaluating the effects of berberine in animal models of diabetic nephropathy. Berberine improved renal function indicators, inflammatory markers, and oxidative stress indicators, suggesting its potential anti-fibrotic, anti-inflammatory, and anti-oxidative stress properties.
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.
This systematic review and meta-analysis evaluated the effects of berberine supplementation on cardiovascular risk factors in adults. The results showed that berberine significantly reduced triglycerides, total cholesterol, low-density lipoprotein, fasting blood glucose, insulin, HbA1c, HOMA-IR, systolic blood pressure, weight, and body mass index, while increasing high-density lipoprotein. Optimal doses varied for different outcomes.
Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis.
Systematic review and meta-analysis of three randomized controlled trials with 1076 patients assessing berberine's efficacy and safety in preventing colorectal adenomas recurrence. Berberine supplementation for 1-2 years was associated with a lower recurrence rate of colorectal adenomas but had more adverse events than placebo, with constipation being the most common.
Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study.
This multi-center, double-blind, randomized, parallel-controlled study assessed the hypoglycemic effect and gut microbiota regulation of berberine and Bifidobacterium in 297 participants with hyperglycemia. Significant reductions in fasting plasma glucose and 2-hour postprandial plasma glucose were observed in the berberine and combination groups compared to placebo. The combination group also showed a pronounced decrease in HbA1c and changes in gut microbiota.
Pre-clinical Evidence: Berberine as a Promising Cardioprotective Candidate for Myocardial Ischemia/Reperfusion Injury, a Systematic Review, and Meta-Analysis.
Systematic review and meta-analysis of pre-clinical studies on berberine's cardioprotective effects against myocardial ischemia/reperfusion injury. Berberine significantly reduced myocardial infarct size, incidence of ventricular arrhythmia, and biomarkers of myocardial infarction, while improving cardiac function in animal models.
Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Systematic review and meta-analysis of 18 RCTs evaluating the effect of berberine alone on metabolic disorders. Berberine was found to improve obesity and hyperlipidemia by reducing triglycerides, total cholesterol, and LDL, while increasing HDL. It also reduced insulin resistance, improving type II diabetes, and prevented diabetic encephalopathy.
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of RCTs assessing berberine's efficacy and safety in type 2 diabetic patients. Berberine significantly reduced HbA1c, fasting plasma glucose, and 2-hour postprandial blood glucose, improved insulin resistance, and ameliorated lipid profiles and inflammation factors.
Berberine for diarrhea in children and adults: a systematic review and meta-analysis
Systematic review and meta-analysis of 38 RCTs involving 3948 participants assessing berberine for diarrhea treatment. Berberine, alone or with other treatments, improved clinical cure rates and reduced diarrhea duration compared to control groups. No severe adverse events were reported, but evidence quality was moderate to low.
[Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia].
Systematic review and meta-analysis of 25 trials with 3,042 cases evaluating berberine for dyslipidemia. Berberine alone or with lipid-lowering drugs reduced TC, TG, LDL-C levels and increased HDL-C levels compared to control. No severe adverse effects were reported, but trial quality was generally low.
Effects of berberine and barberry on anthropometric measures: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 12 RCTs with 849 subjects on the effects of berberine and barberry on anthropometric measures. Berberine showed a significant reduction in waist-hip ratio, but no significant changes in BMI, body weight, or waist circumference.
Berberine for the treatment of hypertension: A systematic review.
Systematic review of berberine's effect on blood pressure and cardiovascular disease risk, including five RCTs and two non-randomised trials with 614 participants. Berberine showed a moderate reduction in systolic blood pressure compared to metformin, but effects could not be reliably attributed to berberine alone. The evidence was limited, of low quality, and inconclusive.
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study.
This multicentre, double-blinded, randomised controlled trial investigated the efficacy and safety of berberine for preventing colorectal adenoma recurrence. Berberine significantly reduced the risk of adenoma recurrence compared to placebo, with 36% recurrence in the berberine group versus 47% in the placebo group. No serious adverse events were reported.
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).
RCT with 409 newly diagnosed T2D patients comparing 12-week treatments of berberine alone, probiotics+berberine, probiotics alone, or placebo. Berberine and probiotics+berberine groups showed significant reductions in glycated haemoglobin compared to placebo and probiotics alone. Berberine's hypoglycaemic effect is linked to inhibition of DCA biotransformation by Ruminococcus bromii.
The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.
This meta-analysis and systematic review evaluated the effects of berberine supplementation on obesity indices in humans. The analysis included 10 studies and found that berberine significantly reduced BMI and waist circumference, but not body weight.
The effect of Berberine on weight loss in order to prevent obesity: A systematic review.
This systematic review evaluates the efficacy of Berberine on obesity management and related metabolic consequences across in vitro, animal, and human studies. Berberine affects gut microbiota, glucose metabolism, adipocyte differentiation, and lipid levels, showing potential benefits in obesity treatment and prevention.
The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials.
This systematic review and meta-analysis of 12 RCTs analyzed the effects of berberine on anthropometric parameters, CRP, and liver enzymes. Berberine significantly decreased body weight, BMI, waist circumference, and CRP levels, but had no significant effect on liver enzymes ALT and AST.
Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
Systematic review evaluating the therapeutic potential of berberine for preventing dementia associated with diabetes and metabolic syndrome. The review found that berberine enhances cholinergic neurotransmission, improves cerebral blood flow, protects neurons from inflammation, and has beneficial effects against diabetes and associated disorders, suggesting both direct and indirect benefits for dementia prevention.
The effect and safety of Berberine on polycystic ovary syndrome: a systematic review.
Systematic review assessing the effect of Berberine on women with polycystic ovary syndrome. Berberine significantly decreased waist to hip ratio, insulin resistance, and androstenedione levels, but had no significant effect on body weight, FSH, and LH.
The Efficacy of Berberine-Containing Quadruple Therapy on Helicobacter Pylori Eradication in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Systematic review and meta-analysis of RCTs evaluating berberine-containing quadruple therapy for Helicobacter pylori eradication. The addition of berberine significantly improved eradication rates, peptic ulcer healing, symptom relief, and reduced adverse events compared to standard triple therapy.
Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Systematic review and meta-analysis of 11 RCTs involving 1386 patients evaluating berberine alone or combined with statins for hyperlipidemia. Berberine significantly reduced total cholesterol and LDL levels, and increased HDL levels compared to placebo. Berberine plus simvastatin was more effective in reducing triglyceride and total cholesterol levels compared to simvastatin alone. Adverse reactions were lower with berberine, except for higher constipation incidence.
The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials
Systematic review and meta-analysis of 12 RCTs assessing berberine's effects on reproductive and metabolic outcomes in women with PCOS. Berberine showed mixed results on live birth rates but improved insulin resistance, dyslipidemia, and decreased androgen levels and LH/FSH ratio compared to metformin.
Metabolic effect of berberine-silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials.
Meta-analysis of RCTs assessing the impact of berberine and silymarin combination on serum lipids and fasting plasma glucose. The combination showed positive effects on total cholesterol, triglycerides, HDL-C, LDL-C, and fasting plasma glucose, suggesting potential benefits for cardiometabolic health.
Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis.
Systematic review and meta-analysis of 28 studies with 2,313 type 2 diabetes mellitus patients evaluating the effect of Berberine on blood glucose. Berberine treatment was associated with significant reductions in fasting plasma glucose, postprandial plasma glucose, and glycated haemoglobin levels compared to control groups. The effect was less pronounced with treatment durations over 90 days, dosages over 2 g/d, and in patients over 60 years old.
Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.
Systematic review and meta-analysis of 16 RCTs with 2147 participants evaluating berberine for dyslipidaemias. Berberine significantly reduced total cholesterol, LDL-C, and triglycerides, and increased HDL-C, with no significant differences in adverse events. Findings should be interpreted with caution due to high heterogeneity and risk of bias.
Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials.
Meta-analysis of 11 RCTs evaluating the effects of a nutraceutical combination containing berberine, policosanol, and red yeast rice on lipid profiles in hypercholesterolemic patients. The combination significantly improved lipid parameters, including reductions in total cholesterol and LDL-c, and increases in HDL-c.
Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
Meta-analysis of 27 RCTs with 2569 patients assessing berberine's efficacy and safety in treating type 2 diabetes mellitus, hyperlipidemia, and hypertension. Berberine showed comparable effects to standard treatments with no serious side effects, suggesting it as a cost-effective alternative for patients with low socioeconomic status.
The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials.
This meta-analysis of 11 randomized controlled trials with 874 participants assessed the effects of berberine on blood lipid profiles. Berberine significantly reduced total cholesterol, triglycerides, and low-density lipoprotein cholesterol levels, while increasing high-density lipoprotein levels. No serious adverse effects were reported.
A randomized, double-blind, parallel-arm clinical trial to assess the bioavailable efficacy of LipokonTM Berberine and Berberine extract in patients with type 2 diabetes mellitus.
This randomized, double-blind, parallel-arm clinical trial assessed the efficacy of LipokonTM Berberine and Berberine extract in patients with type 2 diabetes mellitus. Both treatment groups showed significant reductions in fasting plasma glucose, post-meal plasma glucose, and HbA1c levels, with improvements in insulin resistance, lipid metabolism, metabolic syndrome severity, and quality of life. The formulation was well-tolerated with no serious adverse events.
Comparative study of efficacy and safety of berberine hydrochloride versus metformin in newly diagnosed prediabetic patients: a randomized clinical trial
A randomized clinical trial comparing the efficacy and safety of Berberine HCl versus Metformin in newly diagnosed prediabetic adults. Berberine HCl showed comparable glycemic efficacy to Metformin with fewer gastrointestinal adverse events, suggesting its potential as an alternative therapy.
The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial.
This double-blind, randomized, placebo-controlled trial investigated the effects of berberine (BBR) on vascular function parameters in individuals with Metabolically Associated Fatty Liver Disease (MAFLD). Berberine supplementation led to a significant increase in VEGF concentrations and a reduction in PWA-SP, suggesting potential vascular and reparative benefits. No significant differences were observed in arterial stiffness parameters between the BBR and placebo groups.
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production.
The study investigates the effects of berberine (BBR) and its metabolite dihydroberberine (dhBBR) on cholestatic liver disease (CLD) in mouse models and a clinical trial. BBR is metabolized by gut microbiota, reducing 5-HT production and ameliorating CLD. Clinical results showed improved blood biochemical indicators and decreased 5-HT levels in patients with CLD.
Novel Wound Care Practices in Bullous Pemphigoid: A Systematic Review.
Systematic review and meta-analysis of wound care practices in bullous pemphigoid, assessing ozone liquid dressing, recombinant human type XVII collagen, and berberine-based dressings. OLD and RHCXVII were associated with faster wound healing and improved outcomes. Berberine 'stamp therapy' showed symptomatic benefit as a topical adjunct.
The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial.
RCT investigating the effects of berberine and cinnamon supplementation in patients with type 2 diabetes. The study found that 12 weeks of supplementation reduced fasting blood sugar, HbA1c, and LDL-C levels compared to placebo.
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.
This randomized, double-blind, placebo-controlled trial investigated the effects of berberine (BBR) on patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Seventy individuals were assigned to receive either BBR or placebo for 12 weeks. The BBR group showed significant improvements in alanine transaminase (ALT), de Ritis ratio, and total cholesterol compared to the placebo group, indicating a positive impact on MAFLD-related parameters.
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes.
RCT comparing high and low compression HIIT with or without berberine supplementation in 54 middle-aged men with prediabetes. All exercise interventions reduced hs-CRP, IL-1β, insulin, FBG, and HOMA-IR versus control. Berberine alone significantly reduced FBG and HOMA-IR compared to baseline, but adding berberine to exercise did not show additional benefits.
Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans.
The study investigated the effects of OCT1 and CYP2D6 polymorphisms on berberine pharmacokinetics in humans. It found that CYP2D6 polymorphisms significantly affected berberine metabolism in females, with poor CYP2D6 metabolizers having an 80% lower M1-to-berberine ratio. Berberine displayed low oral bioavailability, with females having a higher AUC and Cthan males.
Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study)
The BRIEF-SIBO study is a randomized controlled trial comparing the effects of berberine and rifaximin on small intestinal bacterial overgrowth (SIBO) in 180 patients. The trial aims to evaluate berberine's efficacy in improving gut health by assessing breath test results, abdominal symptom relief, and gut microbiota alterations over a 6-week period.
Effect of Berberine Phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial.
A multi-centric, randomized, controlled trial studied the effects of Berberine Phytosome (BP) supplementation in 130 Pakistani women with PCOS. BP supplementation led to resumption of regular menstruation in about 70% of women, normalization of ovaries anatomy in over 60%, acne improvement in 50%, and hirsutism reduction in 14%. The metabolic and hormonal profiles did not significantly differ between groups. BP was well-tolerated with no specific side-effects.
Effect of dietary supplementation with a new nutraceutical formulation on cardiometabolic risk factors: a double-blind, placebo-controlled, randomized clinical study
Double-blind, placebo-controlled RCT of 80 mildly hypercholesterolemic patients testing a nutraceutical formulation containing berberine, red yeast rice, milk thistle, and guggul. The formulation significantly reduced total cholesterol, LDL-C, non-HDL cholesterol, apoB, and high-sensitivity C-reactive protein, and improved endothelial reactivity over 8 weeks.
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial.
RCT evaluating berberine as an adjuvant for antipsychotic-associated weight gain and metabolic syndrome in 113 patients with schizophrenia. Berberine group showed significant reductions in weight gain, BMI, cholesterol, LDL, and glycated hemoglobin compared to placebo, with no serious adverse events.
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.
This randomized, double-blind, placebo-controlled clinical trial tested the effect of adjunctive berberine treatment on negative symptoms in patients with schizophrenia. Berberine (900 mg/day) significantly improved the negative symptom subscale of PANSS and decreased plasma CRP concentration over 8 weeks, suggesting an anti-inflammatory effect.
Effects of treatment with monacolin K, berberine and coenzyme Q10 on lipid metabolism in patients with moderate cardiovascular risk.
RCT evaluating the effects of a nutraceutical preparation containing monacolin K, berberine, and coenzyme Q10 on lipid metabolism in patients with moderate hypercholesterolemia and cardiovascular risk. The intervention group showed a significant decrease in LDL-C, non-HDL-C, and total cholesterol compared to placebo, with a good tolerance and safety profile.
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.
RCT of 132 patients with schizophrenia, bipolar disorder, or schizoaffective psychosis treated with olanzapine, comparing berberine to placebo for 12 weeks. Berberine improved metabolic markers and altered gut microbiota composition, reducing firmicutes and increasing bacteroides.
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial.
RCT in 84 Chinese men with hyperlipidemia comparing berberine to placebo for 12 weeks. Berberine reduced total cholesterol and possibly LDL-c, and may increase testosterone, suggesting sex-specific effects. No serious adverse events reported.
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
This randomized, double-blind, placebo-controlled clinical trial studied the effect of berberine (900mg/day) as an adjunctive treatment on glycolipid metabolism in patients with schizophrenia over eight weeks. Berberine significantly reduced total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance compared to placebo.
Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial.
RCT evaluating a 12-week add-on therapy with a nutraceutical formulation (BHC) containing berberine, hesperidin, and chromium picolinate in T2D patients on metformin. The BHC group showed significant improvements in glucose control (FBG and HbA1c) and reductions in AGEs and MDA compared to the control group.
An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia
RCT of 148 patients with dysglycemia evaluating a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate. The nutraceutical improved fasting and post-prandial plasma glucose, glycated hemoglobin, fasting plasma insulin, and reduced total cholesterol, triglycerides, and high sensitivity C-reactive protein compared to placebo.
Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk
RCT of 96 statin-intolerant hypercholesterolemic subjects evaluating a nutraceutical compound (NC) containing Monacolin-K, Berberine Hydrochloride, t-Resveratrol, Quercetin, and Chromium combined with ezetimibe. The combination therapy improved total cholesterol and LDL cholesterol levels more than ezetimibe alone, with no significant changes in triglycerides or HDL cholesterol. The therapy was well tolerated with no withdrawals.
Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis.
Systematic review and meta-analysis of 26 animal studies from 2000 to 2018 examining berberine's effects on various cancers. Berberine reduced tumor volume and weight, inhibited angiogenesis, and showed anti-tumor effects, particularly in breast and lung cancer models.
Neuroprotective effects of berberine in animal models of Alzheimer's disease: a systematic review of pre-clinical studies.
Systematic review of 15 pre-clinical studies on the neuroprotective effects of berberine in Alzheimer's disease animal models. Berberine showed significant memory-improving activities through mechanisms like anti-inflammation, anti-oxidative stress, cholinesterase inhibition, and anti-amyloid effects.
Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of randomized controlled trials assessing the effects of berberine on C-reactive protein (CRP) levels. The analysis included 5 studies and found that berberine supplementation decreased serum CRP levels, suggesting a potential benefit in reducing chronic inflammation.
Berberine Combined with Triple Therapy versus Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials
Meta-analysis assessing the effects and safety of berberine combined with triple therapy on Helicobacter pylori eradication in adults. Results indicated that berberine improved eradication rates and reduced adverse effects such as nausea and diarrhea compared to triple therapy alone.
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Open-label randomized phase IV trial comparing 14-day berberine-containing quadruple therapy to bismuth-containing therapy for H pylori eradication in 612 treatment-naive patients. The berberine regimen showed similar eradication rates and adverse event profiles, suggesting it as a viable alternative.
Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review.
Systematic review of clinical trials evaluating berberine for the treatment of hyperlipidemia and dyslipidemias. The review found that berberine consistently reduces low-density lipoprotein and triglycerides, suggesting it as an alternative for patients intolerant to statins or resistant to starting statin therapy.
Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome.
A multicenter randomized double-blinded placebo-controlled trial comparing letrozole, berberine, and their combination in 644 women with PCOS. The study found that cumulative live births were similar between the letrozole and combination groups, both superior to the berberine group. Berberine did not enhance fecundity when combined with letrozole.
A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs.
Systematic review of berberine's anticancer properties, highlighting its inhibitory effects on tumorigenic microorganisms and viruses, transcriptional regulation of oncogenes, and enzyme inhibition. Berberine shows potential as an alternative medicine for tumor chemotherapy by suppressing tumor growth and metastasis and improving multidrug resistance.
[Advances in the study of berberine and its derivatives].
Systematic review of research advances on berberine and its derivatives, covering clinical applications, pharmacodynamic mechanisms, molecular pharmacology, absorption and metabolism, and structure-activity relationship studies. Highlights berberine's potential for structural modification as a new drug lead.
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial.
This retrospective cohort study is a 6-year follow-up of a previous clinical trial evaluating the long-term protective effects of berberine on colorectal adenoma recurrence. Among 781 patients, berberine showed a lower adenoma recurrence rate (34.7% vs. 52.1%) and lower neoplasm occurrence rate (63.4% vs. 71.0%) compared to controls.
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial.
RCT of 49 overweight subjects with impaired fasting blood glucose comparing berberine phytosome supplementation to placebo over 60 days. Berberine significantly improved glycemia, total cholesterol, triglycerides, insulin, and body composition metrics without adverse events.
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection.
RCT evaluating berberine's efficacy in improving metabolic syndrome in HIV patients. Berberine group showed reductions in weight, BMI, insulin resistance, and TNF-alpha, while the control group had higher cholesterol and IL-6 levels.
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial.
A randomized, double-blinded, placebo-controlled trial was conducted for 12 weeks among 34 individuals with prediabetes to evaluate the effect of daily oral berberine on glycemic control and insulin resistance. Significant decreases in all markers of glycemic control were observed in the treatment group compared to baseline levels and the control group, with no severe adverse effects detected.
Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans.
RCT with 12 healthy subjects comparing absorption of 800 mg berberine in powder form versus emulsified with vitamin E TPGS or Quillaja extract. Emulsification significantly increased the area under the curve (AUC) and peak plasma concentration of berberine, with Quillaja extract being more effective than TPGS. Metabolism of berberine was not affected by emulsification.
Effects of a Mixture of Ivy Leaf Extract and Coptidis rhizome on Patients with Chronic Bronchitis and Bronchiectasis
Observational study of 304 patients with chronic bronchitis and bronchiectasis treated with a combination of ivy leaf extract and Coptidis rhizome for 12 weeks. Significant improvements were observed in St. George’s Respiratory Questionnaire scores and bronchitis severity scores. No serious adverse reactions were reported.
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel.
The study investigates berberine (BBR) as an insulin secretagogue targeting KCNH6 potassium channels. In a phase 1 clinical trial with 15 healthy men, BBR significantly promotes insulin secretion under hyperglycemic conditions compared to placebo, without affecting basal insulin secretion. BBR is well-tolerated with no side effects observed in a 14-day follow-up.